China SXT Pharmaceuticals, Inc. (SXTC)
NASDAQ: SXTC · IEX Real-Time Price · USD
1.020
+0.030 (3.03%)
Apr 19, 2024, 4:00 PM EDT - Market closed

Company Description

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China.

The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.

It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China.

China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

China SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals logo
Country China
Founded 2005
IPO Date Jan 4, 2019
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 78
CEO Feng Zhou

Contact Details

Address:
178 Taidong Road North
Taizhou, F4 225300
China
Phone 8652386298290
Website sxtchina.com

Stock Details

Ticker Symbol SXTC
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
IPO Price $4.00
CIK Code 0001723980
CUSIP Number G2161P108
ISIN Number VGG2161P1403
SIC Code 2834

Key Executives

Name Position
Feng Zhou Chairman of the Board and Chief Executive Officer
Xiaodong Pan Chief Financial Officer
Jun Zheng Executive Director

Latest SEC Filings

Date Type Title
Apr 5, 2024 6-K Report of foreign issuer
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 11, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jul 31, 2023 20-F Annual and transition report of foreign private issuers
May 19, 2023 20-F/A Filing
Mar 29, 2023 SC 13G Statement of acquisition of beneficial ownership by individuals
Mar 29, 2023 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 27, 2023 424B7 Filing
Mar 23, 2023 6-K Report of foreign issuer